Daniel Lu
Overview
Explore the profile of Daniel Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Febres-Aldana C, Vojnic M, Odintsov I, Zhang T, Cheng R, Beach C, et al.
Cancer Discov
. 2025 Feb;
PMID: 39965191
MET fusions (MET-Fs) are oncogenic drivers that remain poorly characterized. Analysis of 56 MET-F-positive tumors from an institutional cohort of 91,119 patients (79,864 DNA-seq plus 11,255 RNA-seq) uncovered two forms...
2.
Steitieh D, Beale R, Katznelson E, Feldman E, Minutello D, Lu D, et al.
Int J Cardiol
. 2025 Feb;
426:133054.
PMID: 39929310
Background: In October 2018, a new heart allocation policy was implemented to risk stratify patients listed for transplant, prioritizing patients supported with temporary mechanical circulatory support (MCS). The policy changes...
3.
Okun S, Lu D, Sew K, Subramaniam A, Lockwood W
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39858062
The hepatocyte growth factor receptor (MET) is a receptor tyrosine kinase (RTK) that mediates the activity of a variety of downstream pathways upon its activation. These pathways regulate various physiological...
4.
Amrute J, Lee P, Eres I, Lee C, Bredemeyer A, Sheth M, et al.
medRxiv
. 2024 Nov;
PMID: 39606421
Although genome wide association studies (GWAS) in large populations have identified hundreds of variants associated with common diseases such as coronary artery disease (CAD), most disease-associated variants lie within non-coding...
5.
Luu J, Johnson F, Jajarmi J, Sihota T, Shi R, Lu D, et al.
Front Oncol
. 2024 Jan;
13:1286821.
PMID: 38260835
Background: Lung cancer is the leading cause of cancer related death worldwide, mainly due to the late stage of disease at the time of diagnosis. Non-invasive biomarkers are needed to...
6.
Lu D, Parisi L, Gokcumen O, Atilla-Gokcumen G
RSC Chem Biol
. 2023 Apr;
4(4):310-322.
PMID: 37034406
Necroptosis is a type of programmed cell death. It is characterized by membrane permeabilization and is associated with the release of intracellular components due to compromised membrane integrity which induces...
7.
Farnsworth D, Inoue Y, Johnson F, de Rappard-Yuswack G, Lu D, Shi R, et al.
NPJ Precis Oncol
. 2022 Nov;
6(1):88.
PMID: 36418460
MEK inhibitors (MEKi) have limited efficacy in KRAS mutant lung adenocarcinoma (LUAD) patients, and this is attributed to both intrinsic and adaptive mechanisms of drug resistance. While many studies have...
8.
Zhang Y, Jost M, Pak R, Lu D, Li J, Lomenick B, et al.
Proc Natl Acad Sci U S A
. 2022 Aug;
119(36):e2205608119.
PMID: 36037385
Cop9 signalosome (CSN) regulates the function of cullin-RING E3 ubiquitin ligases (CRLs) by deconjugating the ubiquitin-like protein NEDD8 from the cullin subunit. To understand the physiological impact of CSN function...
9.
Lu J, Swearingen E, Hardy M, Collins P, Wu B, Yuan E, et al.
Mol Ther Nucleic Acids
. 2022 May;
28:423-434.
PMID: 35505960
Small interfering RNA (siRNA) therapeutics have developed rapidly in recent years, despite the challenges associated with delivery of large, highly charged nucleic acids. Delivery of siRNA therapeutics to the liver...
10.
Lu D, Nagelberg A, Chow J, Chen Y, Michalchuk Q, Somwar R, et al.
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326531
Targeted therapies for exon 14-skipping ()-driven lung cancers have generated some promising results but response rates remain below that seen for other kinase-driven cancers. One strategy for improving treatment outcomes...